Comparing a personalised risk tool with usual care for ovarian cancer risk
Compares two ways to estimate ovarian cancer risk in cancer-free people.
Plain-language title generated from the registry record
Registry title: CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
Key facts
- Where
- Kaunas, LithuaniaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07809659, who can take part
Where in Lithuania
- Lithuanian University of Health SciencesKaunas, LithuaniaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
- Trial code
- NCT07809659
- Record updated
- 29 September 2026
- Original description
The purpose of this study is to improve how the risk of developing ovarian cancer is assessed in people who may be at increased risk of ovarian cancer due to their family history or genetic background.Read full original descriptionShow less
Operationalising Multifactorial Ovarian Cancer Risk Assessment Using the CanRisk Tool Versus Standard Practices.
The purpose of this study is to improve how the risk of developing ovarian cancer is assessed in people who may be at increased risk of ovarian cancer due to their family history or genetic background.
In current clinical practice, ovarian cancer risk assessment usually relies on information about cancer in the family and, in some cases, genetic testing for certain genes known to be associated with ovarian cancer. While this approach is commonly used, the inclusion of additional factors may support more personalised ovarian cancer risk assessment.
This study compares two approaches to ovarian cancer risk assessment:
* Standard clinical practice, which follows current national guidelines, and * A more personalised risk assessment, which uses a validated tool called CanRisk, recommended by European guidelines, to combine family history, genetic test results, and other factors, including health and lifestyle-related factors.
By comparing these two approaches, the study aims to understand whether the personalised risk assessment tool, CanRisk, can be used in everyday clinical care. To do this, researchers will investigate whether the CanRisk tool is feasible in clinical practice, acceptable to both healthcare professionals and persons receiving a risk assessment, as well as whether it can be delivered in a cost-effective way.
The study does not involve people who have been diagnosed with ovarian cancer. It focuses on individuals who are currently cancer-free and are undergoing assessment because they may have an increased risk of ovarian cancer.
Inclusion: Women, trans men, non-binary people with female reproductive organs; Aged 18 to 75 years; Referred or self-referred because of a family history suggestive of increased risk for ovarian, fallopian tube or peritoneum cancer, or because a family member has been found to have a PV associated with OC risk; Able to give informed consent; Expected to remain in the study catchment area for the duration of follow-up.
Exclusion: Previously undergone Risk-Reducing Salpingo-Oophorectomy (RRSO); Previously undergone multifactorial risk assessment (using CanRisk or another tool) incorporating risk factors, family history and genetic testing (panel +/- PGS); Personal history of cancer; Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements.